Leaps by Bayer’s Post

Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest The new study looked at how the drug performed in about 95 per cent of trial patients who continued on the treatment. After three years, Leqembi slowed cognitive decline by 31 per cent compared to what would be expected in similar patients who did not receive treatment. #Alzheimersdrug I #amyloidplaques I #protofibrils I #cognitivedecline I #amyloidplaques I Eisai Co., Ltd. I Biogen Read more: https://lnkd.in/gh3yV8t8

While there is no cure for Alzheimer’s, research is working towards developing drug treatments that slow the progression of the disease in early stages. The newest drug called Donanemab, follows Leqembi, which also won U.S. approval last year. Both drugs are designed to remove toxic beta amyloid plaques from the brains of people with early Alzheimer's disease. The antibody treatments, which succeeded in slowing disease progression in clinical trials, follow three decades of failed attempts to find drugs to fight the fatal mind-wasting disease. Full Reuters article here: https://lnkd.in/gri5GYjK #dementiaawareness #AlzheimersAwareness

💡 Breaking boundaries in drug delivery, this study explores the transformative potential of pulmonary delivery. Inhaled treatments, once solely for treating respiratory ailments, are now pivotal for managing a diverse array of diseases, from diabetes to neurological disorders. Our research highlights particle engineering strategies such as spray drying, and the use of protective additives like trehalose and mannitol are making high-dose medications and biologics more manageable. This new approach promises a more effective delivery system for patient care. These advancements in drug formulation processing techniques are charting the future course for treating diseases like lung cancer, pulmonary hypertension, and Alzheimer's. But it's not just about convenience; it's about bringing targeted, efficient healthcare solutions to patients worldwide. Curious to know more? We invite you to explore the full article published here: https://lnkd.in/dHDYztvt Authors: Pauline van der Wijst - Janssen, Ross Blezard

According to a study published in Alzheimer's & Dementia journal, as of January 2023, a whopping 187 clinical trials were underway, testing 141 potential medications for various stages of Alzheimer's. The focus? Disease-modifying medications, a remarkable shift from symptom management, making up 79% of these trials. This groundbreaking commitment involved biologics, medical devices, and small-molecule drugs, reflecting a collective effort to transform the landscape of Alzheimer's treatment. There's not just diversity in types but also in drug targets, with the potential drugs belonging to 12 different target classes, showcasing a multifaceted approach to tackling Alzheimer's. The study estimated that 57,465 participants are needed for these trials. Although a modest number compared to the fact that about 5-6 million Americans are affected by Alzheimer's symptoms today, recruitment for studies remains a major headache. Yet, there's hope! The dedication, innovativeness, and investment in these trials signal a brighter future in the fight against Alzheimer's. Disease-modifying medications stand out as a beacon of progress. Let's spread awareness and optimism together! 💙🤝 #EndAlz #ClinicalTrials #AlzheimersResearch #HopeInTheFight Read more: [https://lnkd.in/gJNpSe-w]

🌟 Overview of Parkinson’s Research! 🌟 The latest annual report from the Michael J. Fox Foundation, Cure Parkinson’s, and Parkinson’s research advocates reveals that the number of Parkinson’s drug trials has remained remarkably consistent over the past five years, despite global challenges. 🔬 Key Highlights: 136 active clinical trials as of January 31, 2024. 56% of trials focus on symptomatic treatments, while 44% aim to modify the disease1. 58% of trials are in Phase 2, but only 12% have reached Phase 3. It is clear that the need for more late-stage trials to advance disease-modifying therapies is required to tackle Parkinson's. Let’s continue to support and drive forward these crucial efforts towards finding a cure for Parkinson’s! 💪 #ParkinsonsResearch #CureParkinsons Reference: Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update - IOS Press

Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. Thus, there is an urgent need to validate and translate biomarkers as tools for daily clinical practice. PRIME-CKD has a unique advantage to address this challenge as it builds on recently discovered pharmacodynamic biomarkers for CKD treatment, and has access to a vast amount of clinical data, bio-samples. https://lnkd.in/duyQTtSR

Biologic therapies have revolutionized cancer care. Despite many efforts, many people in emerging countries still lack access to these advanced treatments.  At Abbott, we help people reach their full potential through good health. We help break barriers to health so that more people can get and stay healthy. In our medicines business, we broaden access to biosimilars, versions of original biologics produced after the patent expires, so that more people in emerging countries can benefit from these life-changing treatments. Biosimilars can help #CloseTheCareGap and increase #healthequity. I feel incredibly fortunate to work towards building health equity by helping to broaden access to care so that more people can live longer, healthier lives.   Read more about what biosimilars can mean for emerging countries: [link] [https://lnkd.in/eS7wnH9q] #AbbottProud #CancerCare #Biosimilars #CloseTheCareGap

Did you know that only about 5% of rare diseases have FDA-approved treatments? Yet, up to 15% of these diseases show promise with at least one potential drug in development. The global orphan drug industry is evolving rapidly, driven by a growing demand for innovative solutions to address unmet medical needs in rare diseases. Interested in learning more about the emerging opportunities driving growth in the orphan drug industry? Download a sample of our latest Growth Opportunity Content here: https://bit.ly/3WtD8N4 #OrphanDrugIndustry #RareDiseases #PrecisionMedicine #Innovation #GrowthOpportunities

Did you know that only about 5% of rare diseases have FDA-approved treatments? Yet, up to 15% of these diseases show promise with at least one potential drug in development. The global orphan drug industry is evolving rapidly, driven by a growing demand for innovative solutions to address unmet medical needs in rare diseases. Interested in learning more about the emerging opportunities driving growth in the orphan drug industry? Download a sample of our latest Growth Opportunity Content here: https://bit.ly/3UBu1bX #OrphanDrugIndustry #RareDiseases #PrecisionMedicine #Innovation #GrowthOpportunities